Overview

Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines

Status:
Completed

Trial end date:
2015-03-16

Target enrollment:

Participant gender:

Summary

The purpose of this first time in human (FTiH) study is to evaluate the safety, reactogenicity and immunogenicity of several formulations of Respiratory Syncytial Virus (RSV) investigational vaccines in healthy men.

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Vaccines